Showing 3961-3970 of 5623 results for "".
- Bausch + Lomb Acquires AcuFocushttps://modernod.com/news/bausch-lomb-acquires-acufocus/2481353/Bausch + Lomb announced it has acquired AcuFocus, maker of the IC-8 Apthera IOL. Financial terms of the deal were not disclosed. The moves bolsters Bausch + Lomb's cataract surgery portfolio. AcuFocus' IC-8 was approved by the FDA in July
- Visus Therapeutics Appoints Eric D. Donnenfeld, MD, to Board of Directorshttps://modernod.com/news/visus-therapeutics-appoints-eric-d-donnenfeld-md-to-board-of-directors/2481347/Visus Therapeutics announced the appointment of Eric D. Donnenfeld, MD, to the company’s Board of Directors. Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert in refractive, cornea, and cataract surgery. “I am thrill
- Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerabilityhttps://modernod.com/news/glaukos-announces-positive-results-for-idose-tr-exchange-trial-highlighting-favorable-safety-and-tolerability/2481346/Glaukos announced positive results for a prospective, multicenter clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the phase
- Staar Surgical Announces Partnership with Actress Peyton Listhttps://modernod.com/news/staar-surgical-announces-partnership-with-actress-peyton-list/2481344/Staar Surgical announced a partnership with actress and beauty entrepreneur, Peyton List, to promote the EVO Implantable Collamer Lenses (EVO), which recevied FDA approval in 2022 for the correction of myopia with or without astigmatism. In December 2022, Ms. Li
- Rayner Launches ‘Peer2Peer: The Podcast’ for Clinical Educationhttps://modernod.com/news/rayner-launches-peer2peer-the-podcast-for-clinical-education/2481342/Rayner announced the launch of the latest addition to their Peer2Peer clinical education platform, "Peer2Peer: The Podcast." Topics included in the podcase include the do's and don’ts of implanting toric IOLs; marketing your clinic online; popular
- Neurotech Pharmaceuticals Appoints Scott Hunter as Chief Commercial Officerhttps://modernod.com/news/neurotech-pharmaceuticals-appoints-scott-hunter-as-chief-commercial-officer/2481341/Neurotech Pharmaceuticals announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eye care experience across both rare disease and specialty markets. “Scott’s appointment as the company&rsquo
- Acelyrin Acquires ValenzaBio, Maker of Treatment Candidate for Thyroid Eye Diseasehttps://modernod.com/news/acelyrin-acquires-valenzabio-maker-of-treatment-candidate-for-thyroid-eye-disease/2481339/Acelyrin announced the acquisition of ValenzaBio, a privately held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction. Financial terms of the deal were not disclosed. The acquisition of ValenzaBi
- Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol-in-presbyopia/2481333/Ocuphire Pharma announced the initiation of the VEGA-2 phase 3 pivotal trial with the first patient enrolled in late December. VEGA-2 is evaluating the efficacy and safety for two labels: Nyxol alone and Nyxol with adjunctive low-dose pilocarpine (LDP) therapy for presbyopia.
- Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmologyhttps://modernod.com/news/bausch-lomb-and-novaliq-announce-publication-of-pivotal-phase-3-data-on-nov03-perfluorohexyloctane-in-ophthalmology/2481330/Bausch + Lomb and Novaliq announced that Ophthalmology has published results from the pivotal phase 3 trial GOBI, which is one of two pivotal phase 3 trials for NOV03 (perfluorohexyloctane). NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) as
- AcuFocus Announces First Commercial Patients Treated With the IC-8 Apthera IOLhttps://modernod.com/news/acufocus-announces-first-commercial-patients-treated-with-the-ic-8-apthera-iol/2481329/AcuFocus announced that Vance Thompson, MD, of Vance Thompson Vision, Sioux Falls, South Dakota has commercially implanted the first patients with the IC-8 Apthera IOL. The first and only small aperture, non-toric extended depth of focus IOL, the Apthera IOL is FDA approved fo